Ghebeh Hazem, Mohammed Shamayel, Al-Omair Abeer, Qattan Amal, Lehe Cynthia, Al-Qudaihi Ghofran, Elkum Naser, Alshabanah Mohamed, Bin Amer Suad, Tulbah Asma, Ajarim Dahish, Al-Tweigeri Taher, Dermime Said
Tumor Immunology Unit, Department of Biological and Medical Research, King Faisal Specialist Hospital and Research Center, PO Box 3354, Riyadh 11211, Saudi Arabia.
Neoplasia. 2006 Mar;8(3):190-8. doi: 10.1593/neo.05733.
B7-H1 molecule increases the apoptosis of tumor-reactive T lymphocytes and reduces their immunogenicity. Breast cancer is the second most common cause of mortality after lung cancer. Direct evidence linking B7-H1 with cancer has been shown in several malignancies; however, its expression in breast cancer has not been investigated. We used immunohistochemistry to investigate the expression of the B7-H1 molecule in 44 breast cancer specimens and to study its correlation with patients' clinicopathological parameters. The expression of B7-H1 was shown in 22 of 44 patients and was not restricted to the tumor epithelium (15 of 44, 34% in tumor cells), but was also expressed by tumor-infiltrating lymphocytes (TIL; 18 of 44, 41%). Interestingly, intratumor expression of B7-H1 was significantly associated with histologic grade III-negative (P = .012), estrogen receptor-negative (P = .036), and progesterone receptor-negative (P = .040) patients. In addition, the expression of B7-H1 in TIL was associated with large tumor size (P = .042), histologic grade III (P = .015), positivity of Her2/neu status (P = .019), and severe tumor lymphocyte infiltration (P = .001). Taken together, these data suggest that B7-H1 may be an important risk factor in breast cancer patients and may represent a potential immunotherapeutic target using monoclonal antibody against the B7-H1 molecule.
B7-H1分子可增加肿瘤反应性T淋巴细胞的凋亡并降低其免疫原性。乳腺癌是继肺癌之后第二大常见死因。在多种恶性肿瘤中已发现将B7-H1与癌症联系起来的直接证据；然而，其在乳腺癌中的表达尚未得到研究。我们采用免疫组织化学方法研究44例乳腺癌标本中B7-H1分子的表达情况，并探讨其与患者临床病理参数的相关性。44例患者中有22例显示B7-H1表达，且不仅限于肿瘤上皮（44例中的15例，肿瘤细胞中占34%），肿瘤浸润淋巴细胞（TIL；44例中的18例，占41%）也表达。有趣的是，肿瘤内B7-H1表达与组织学III级阴性（P = 0.012）、雌激素受体阴性（P = 0.036）和孕激素受体阴性（P = 0.040）患者显著相关。此外，TIL中B7-H1的表达与肿瘤体积大（P = 0.042）、组织学III级（P = 0.015）、Her2/neu状态阳性（P = 0.019）以及严重的肿瘤淋巴细胞浸润（P = 0.001）相关。综上所述，这些数据表明B7-H1可能是乳腺癌患者的一个重要危险因素，并且可能代表使用抗B7-H1分子单克隆抗体的潜在免疫治疗靶点。
